Fellowship · Chicago, IL
Sponsored by University of Chicago Medical Center · Director Wendy Darlington
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 96 citations · Ami Desai, Elizabeth Sokol
CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
The New England journal of medicine · 2023 · 140 citations · James LaBelle
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Nature medicine · 2023 · 115 citations · Ami Desai
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 30 citations · Perry Morocco
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
Neuro-oncology · 2021 · 132 citations · Stewart Goldman
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Neuro-oncology · 2022 · 112 citations · Ami Desai
Compartmentalized metabolism supports midgestation mammalian development.
Nature · 2022 · 105 citations · An Pham
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 25 citations · Wendy Darlington